Zoledronic Acid
Rx
Generic NameZoledronic Acid
Therapeutic ClassBisphosphonate
Max / 24h4 mg IV
Common Dose5 mg IV once yearly (osteoporosis), 4 mg IV q3-4 weeks (hypercalcemia/malignancy)
PregnancyUse only if benefit outweighs risk
Indications ▼
Osteoporosis in postmenopausal women and men
Paget's disease of bone
Hypercalcemia of malignancy
Prevention of skeletal-related events in patients with bone metastases from solid tumors
Mechanism & Pharmacokinetics ▼
Mechanism: Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone, reducing calcium release and bone turnover.
Pharmacokinetics: Administered IV; rapid plasma clearance and uptake into bone. Half-life in bone >10 years. Excreted unchanged primarily via the kidneys.
Dosage & Administration ▼
| Condition | Recommended Dose | Frequency |
|---|---|---|
| Osteoporosis (Postmenopausal) | 5 mg | IV infusion once yearly |
| Hypercalcemia of malignancy | 4 mg | IV over at least 15 minutes, repeat q3-4 weeks if necessary |
| Bone metastases / Paget's | 4 mg | IV q3-4 weeks (metastases), 5 mg once yearly (Paget's) |
Note: Administer via slow IV infusion; ensure adequate hydration before infusion.
Side Effects ▼
Fever, flu-like symptoms
Fatigue, headache
Hypocalcemia
Bone, joint, or muscle pain
Rare: Osteonecrosis of the jaw, renal impairment, atrial fibrillation
Contraindications ▼
Hypocalcemia
Severe renal impairment (CrCl <35 mL/min)
Hypersensitivity to zoledronic acid or other bisphosphonates
Pregnancy unless benefit outweighs risk
Drug Interaction ▼
Other nephrotoxic drugs: increase risk of renal impairment
Loop diuretics: may exacerbate hypocalcemia
Concomitant aminoglycosides: additive hypocalcemic effect
Pregnancy & Lactation ▼
Use only if benefit outweighs risk
Excretion in breast milk unknown; caution advised
Clinical / Research Summary ▼
Therapeutic Role: Potent bisphosphonate for prevention and treatment of bone loss, hypercalcemia, and skeletal complications in malignancy.
Clinical Effectiveness: Reduces vertebral and hip fractures in osteoporosis; lowers skeletal-related events in bone metastases.
Safety Profile: Generally well tolerated; acute-phase reactions common after first infusion. Monitor renal function and electrolytes.
Current Research: Studies focus on long-term fracture prevention, dosing intervals, and combination with other antiresorptives.
Patient Counseling Points ▼
Ensure adequate hydration before and after IV infusion.
Report symptoms of hypocalcemia (tingling, muscle cramps, spasms).
Maintain adequate calcium and vitamin D intake.
Monitor renal function prior to each dose.
Inform dentist prior to dental procedures (risk of osteonecrosis of the jaw).
Storage & Handling ▼
Store between 2-8°C, protect from light and freezing
Keep out of reach of children
Brand Names (Bangladesh & Global) ▼
Medical Disclaimer: This information is intended for educational purposes only and must not replace professional medical advice.
.png)
